Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 1, 2023—Tempus announced that the FDA has approved the company’s premarket approval application for its companion diagnostic test, xT CDx, to identify patients who may benefit from treatment with the targeted therapies listed in the product’s indications for use.
April 27, 2023—Kaiser Foundation Hospitals and Geisinger Health announced the launch of Risant Health and a definitive agreement to make Geisinger the first health system to join Risant to expand access to value-based care in communities across the country.
April 21, 2023—ZeptoMetrix introduced Protrol, a line of products designed to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.
April 18, 2023–Bio-Rad Laboratories has launched Cardiac Advance, a four-level multianalyte cardiac quality control for high-sensitivity troponin testing.
April 14, 2023—LGC SeraCare has developed a comprehensive solid tumor copy number variation reference material in a formalin-fixed, paraffin-embedded format.
April 13, 2023—ARUP Laboratories has selected Gestalt Diagnostics’ PathFlow digital platform to support its vision, ARUP says, for digital pathology.
April 10, 2023—Maine Molecular Quality Controls has released SpotFire RSP positive and negative controls for use as external assayed quality controls to monitor the performance of in vitro laboratory nucleic acid testing for the qualitative detection of Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae, adenovirus, seasonal coronavirus, SARS-CoV-2, human metapneumovirus, human rhinovirus/enterovirus, influenza A subtypes H1-2009 and H3, influenza B, parainfluenza virus, and RSV.
April 3, 2023—Leica Biosystems announced FDA 510(k) clearance of the Bond mismatch repair antibody panel for use in screening patients with colorectal cancer for the identification of Lynch syndrome.
March 31, 2023—Sarstedt’s new Needle-Free Transfer Urine Collection System is a closed urine collection system for needle-free transfer of urine from the needle-free cup or urine collection container to a Urine Monovette.
March 22, 2023—Roche has entered into a collaboration with Eli Lilly to support the development of Roche’s Elecsys Amyloid Plasma Panel.
